公开(公告)号：US20150044231A1

公开(公告)日：2015-02-12

申请号：US14467393

申请日：2014-08-25

Applicant: Novo Nordisk A/S

Inventor： Kristian Kjaergaard ,  Soeren Lund ,  Stefan Zahn ,  Louise H. Zeuthen ,  Anker J. Hansen

IPC: C07K16/28

CPC classification number: C07K16/2896 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.

Abstract translation: 本发明涉及识别人C5a受体的人抗体。 通过结合C5aR，抗体抑制C5a信号传导，从而抑制促炎信号。 基于C5a及其受体在炎症刺激中的作用，本发明进一步涉及所述人类抗C5aR抗体的治疗用途，特别是涉及免疫学疾病的治疗。

公开(公告)号：US20140294853A1

公开(公告)日：2014-10-02

申请号：US14267028

申请日：2014-05-01

Applicant: Novo Nordisk A/S

Inventor： Mette Dahl Andersen ,  Peder Lisby Noerby ,  Kristian Kjaergaard ,  Susanne Nedergaard Grell ,  Albrecht Gruhler ,  Jens Buchardt ,  Henrik Sune Andersen ,  Soeren Padkjaer ,  Jesper Kastrup ,  Katarina Haakansson ,  Lars Hornum ,  Birgitte Friedrichsen ,  Dorrit Baunsgaard

IPC: C07K16/28 ,  A61K47/48

CPC classification number: A61K47/6803 ,  A61K47/545 ,  A61K2039/505 ,  C07K14/70578 ,  C07K16/2863 ,  C07K16/2878 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30

Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.

Abstract translation: 本发明涉及炎性疾病的治疗。 特别地，本发明涉及可用于治疗炎性疾病的拮抗性DR3配体。

公开(公告)号：US08846045B2

公开(公告)日：2014-09-30

申请号：US13920585

申请日：2013-06-18

Applicant: Novo Nordisk A/S

Inventor： Kristian Kjaergaard ,  Soeren Lund

IPC: A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2896 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention concerns human antibodies recognizing the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.

Abstract translation: 本发明涉及识别人C5a受体的人抗体。 通过结合C5aR，抗体抑制C5a信号传导，从而抑制促炎信号。 基于C5a及其受体在炎症刺激中的作用，本发明进一步涉及所述人类抗C5aR抗体的治疗用途，特别是涉及免疫学疾病的治疗。